To reach more patients across Europe, we're now a part of
Blog
- |
- → General
“All predictions say that DCTs are going to explode”: Interview with Dr. med. Bettina Bergtholdt
→ read more
We interviewed Dr. med. Bettina Bergtholdt, the Executive Manager (CEO) of emovis. She shared the company’s origin story with us and told us all about her entrepreneurial journey that began over two decades ago. She also told us about the exciting developments at emovis and about the evolution of the emovis Decentralized Clinical Trials Department. So, what is the big news at emovis? Read this interview to find out more!
- |
- → General
emovis Joins FutureMeds: A Milestone Acquisition for Expanding European Clinical Research and DCT Capabilities
→ read more
We are excited to announce the sale of emovis to FutureMeds, a fast-growing independent European Dedicated Research Site Network that supports pharmaceutical companies, sponsors, and CROs. The fusion of FutureMeds' transformational, fully-owned dedicated research site network model with our proven solutions and expertise promises to bring about clinical trial solutions that will foster stronger partnerships with clients through even higher performance, efficiency, and quality.
- |
- → General
“In the future there will be no difference between conventional and decentralized trials”: An Interview with Rebeca González Vicedo
→ read more
We interviewed Rebeca González Vicedo, the Director of our Decentralized Clinical Trials Department, to learn about her work. Read this interview to find out about her interesting insights on Decentralized Clinical Trials (DCTs) and which unique perspectives emovis has combined to offer its comprehensive DCT service.